Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort
Top Cited Papers
Open Access
- 1 January 2014
- journal article
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 12 (1), 116
- https://doi.org/10.1186/1479-5876-12-116
Abstract
Ipilimumab improves survival in patients with advanced melanoma. The activity and safety of ipilimumab outside of a clinical trial was assessed in an expanded access programme (EAP).Keywords
This publication has 20 references indexed in Scilit:
- Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trialsAnnals of Oncology, 2013
- Resistance to BRAF-targeted therapy in melanomaEuropean Journal Of Cancer, 2013
- Improved Survival with MEK Inhibition in BRAF-Mutated MelanomaNew England Journal of Medicine, 2012
- CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic MelanomaClinical Cancer Research, 2012
- Upcoming strategies for the treatment of metastatic melanomaArchives of Dermatological Research, 2012
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic MelanomaNew England Journal of Medicine, 2011
- Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic MelanomaJournal of Clinical Oncology, 2011
- Targeting BRAF for patients with melanomaBritish Journal of Cancer, 2010
- Development of Ipilimumab: Contribution to a New Paradigm for Cancer ImmunotherapySeminars in Oncology, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010